We are live on ! Find out more
ATYR

aTyr Pharma
ATYR

24 hedge funds and large institutions have $14.7M invested in aTyr Pharma in 2020 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 7 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

267% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 3

83% more capital invested

Capital invested by funds: $8.02M → $14.7M (+$6.67M)

41% more funds holding

Funds holding: 17 → 24 (+7)

6.65% more ownership

Funds ownership: 49.46% → 56.11% (+6.6%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
24
Holders Change
+7
Holders Change %
+41.18%
% of All Funds
0.53%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
11
Increased
7
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Federated Hermes
Federated Hermes
Pennsylvania
+$4.4M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$3.93M
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$3.19M
4
Viking Global Investors
Viking Global Investors
Connecticut
+$1.55M
5
Two Sigma Investments
Two Sigma Investments
New York
+$277K

Top Sellers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
-$8K
Name Holding Trade Value Shares
Change 		Change in
Stake
Federated Hermes
1
Federated Hermes
Pennsylvania
$4.52M +$4.4M +1,019,928 +171%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$3.93M +$3.93M +911,425 +185%
Alyeska Investment Group
3
Alyeska Investment Group
Illinois
$2.07M +$3.19M +738,288 New
Viking Global Investors
4
Viking Global Investors
Connecticut
$1.65M +$1.55M +358,161 +156%
Vanguard Group
5
Vanguard Group
Pennsylvania
$621K +$243K +56,355 +34%
Renaissance Technologies
6
Renaissance Technologies
New York
$585K +$39.2K +9,080 +5%
PVMCV
7
Polaris Venture Management Co V
Massachusetts
$366K – – –
Two Sigma Investments
8
Two Sigma Investments
New York
$180K +$277K +64,269 New
Ensign Peak Advisors
9
Ensign Peak Advisors
Utah
$106K – – –
UBS Group
10
UBS Group
Switzerland
$106K +$149K +34,551 +1,002%
Two Sigma Advisers
11
Two Sigma Advisers
New York
$102K +$157K +36,350 New
Dimensional Fund Advisors
12
Dimensional Fund Advisors
Texas
$78K +$121K +27,924 New
JMPWA
13
JP Morgan Private Wealth Advisors
California
$63K – – –
Millennium Management
14
Millennium Management
New York
$62K +$96.2K +22,284 New
MAM
15
Marquette Asset Management
Minnesota
$53K +$81.4K +18,848 New
OC
16
Oppenheimer & Co
New York
$53K +$81.8K +18,941 New
Citadel Advisors
17
Citadel Advisors
Florida
$52K +$20.9K +4,831 +35%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$36K – – –
Susquehanna International Group
19
Susquehanna International Group
Pennsylvania
$29K +$44.3K +10,268 New
BlackRock
20
BlackRock
New York
$24K – – –
Victory Capital Management
21
Victory Capital Management
Texas
$8K +$11.2K +2,602 New
Bank of America
22
Bank of America
North Carolina
$3K +$4.74K +1,098 New
TRCT
23
Tower Research Capital (TRC)
New York
– -$8K -1,806 Closed
Wells Fargo
24
Wells Fargo
California
– +$199 +46 New

ATYR Hedge Fund Activity: Q1 2020 in Review

24 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q1 2020, worth a combined $14.7M — up 83% from $8.02M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new ATYR positions and 3 closed out — a net gain of 8 holders — while 7 added to existing stakes and 0 trimmed.

The largest buyer was Federated Hermes, adding an estimated $4.4M. The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $8K sold.

  • 24 institutional investors held aTyr Pharma (ATYR) as of Q1 2020, up from 17 in Q4 2019.
  • Funds reported $14.7M of aTyr Pharma stock for Q1 2020, up 83% quarter-over-quarter.
  • 11 funds opened new aTyr Pharma positions in Q1 2020 and 3 closed out, a net change of +8 holders.
  • The largest aTyr Pharma buyer in Q1 2020 was Federated Hermes, an estimated $4.4M added.
  • The largest aTyr Pharma seller in Q1 2020 was Tower Research Capital (TRC), an estimated $8K sold.

Based on aggregated 13F filings for Q1 2020.